Obicetrapib for Antioxidant Levels in Healthy Volunteers
This study is looking into whether Obicetrapib, a drug, can change the levels of antioxidants in your blood and in the tissues of your eyes. Researchers want to see if Obicetrapib helps your body absorb antioxidants better. You would either receive Obicetrapib or a placebo (a substance with no active drug) daily for four months. The study is open to healthy volunteers aged 18 to 75 who have good vision. Success for this study means seeing a change in antioxidant levels in your HDL (high-density lipoprotein, a type of cholesterol) after 16 weeks. The current status of this study is unclear, and it aims to enroll 100 participants.
- Study design
- This is an interventional study comparing Obicetrapib to a placebo, with a planned enrollment of 100 healthy volunteers.
- What's involved
- You would take Obicetrapib or a placebo daily for 4 months, visit the clinic every 8 weeks for checkups, and have blood and eye tests to measure antioxidant levels.
- Compensation
- Not stated in the trial record.
- Follow-up
- Antioxidant levels in HDL will be measured at 16 weeks, indicating the duration of the primary follow-up.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Sum of Percent Change of Antioxidant Levels within HDL16 Weeks
The primary efficacy endpoint is the effect of obicetrapib on the sum of the percent changes in lutein, zeaxanthin, and α-tocopherol levels within HDL particles from baseline to visit 4 (week 16) compared to placebo.